Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma

Fineline Cube Apr 21, 2026
Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Fineline Cube Apr 20, 2026
Company Deals

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

Fineline Cube Apr 20, 2026
Company Deals

SenseTime Raises $73.3 Million in Series A Financing for AI Healthcare Platform – Medical Agentic OS and World Model Capabilities Attract Raffles Healthcare, Lion Partners

Fineline Cube Apr 20, 2026
Company Deals

Mabwell Bioscience Raises $185 Million in Hong Kong IPO After Two Previous Failed Attempts – Oncology and Age-Related Disease Developer Secures HK$1.45 Billion Valuation

Fineline Cube Apr 20, 2026
Policy / Regulatory

China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive

Fineline Cube Apr 21, 2026
Company Drug

Shanghai Leadingtac Secures FDA Clearance for Phase I Trial of LT-010391, First Oral KRAS-G12D Degrader in Clinical Development

Fineline Cube Apr 21, 2026
Company Drug

FDA Grants Priority Review to Merck, Astellas, and Pfizer’s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer

Fineline Cube Apr 21, 2026
Company Deals

Bio-Link Partners with Verdot to Distribute Innovative Bioprocessing Products in China

Fineline Cube Jan 10, 2024

Bio-Link Biological Applied Technologies (Shanghai) Co., Ltd., a leading provider of life sciences industry solutions...

Company Deals

Synvida Raises Nearly RMB 200 Million in Series A Funding to Advance Clinical Studies

Fineline Cube Jan 10, 2024

Synvida, a biotech company incubated by Shanghai Pharma (HKG: 2607, SHA: 601607) and Shanghai Healthcare...

Company Deals Medical Device

Sinocare Partners with Illumina to Localize iScan Chip Scanners for Precision Health Applications

Fineline Cube Jan 10, 2024

Sinocare Inc. (SHE: 300298), a China-based company, has entered into a partnership agreement with U.S....

Company Deals

Johnson & Johnson to Acquire Ambrx Biopharma in a Deal Valued at USD 2 Billion

Fineline Cube Jan 9, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare conglomerate, has announced its intention to...

Company Drug

MSD’s Gardasil 9 Receives NMPA Approval for Two-Dose Schedule in Younger Females

Fineline Cube Jan 9, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK), a prominent pharmaceutical company in the U.S., has...

Company Drug

Astellas’ Zolbetuximab Faces FDA Rejection Due to Manufacturing Facility Deficiencies

Fineline Cube Jan 9, 2024

The US Food and Drug Administration (FDA) has issued a rejection for a filing submitted...

Company Drug

3SBio Inc. Receives NMPA Approval for OTC Minoxidil Foam for Male Hair Loss Treatment

Fineline Cube Jan 9, 2024

3SBio Inc., a leading biopharmaceutical company based in China (HKG: 1530), has announced that it...

Company Deals

MSD to Acquire Harpoon Therapeutics for USD 680 Million, Expanding Its Oncology Pipeline

Fineline Cube Jan 9, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has announced its...

Company

Eli Lilly Appoints First Female Leader for China Unit with Huzur Devletsah at the Helm

Fineline Cube Jan 9, 2024

Eli Lilly and Company (NYSE: LLY), a leading pharmaceutical corporation in the U.S., has announced...

Company Drug

Jiangxi Jemincare Group Receives Clinical Trial Approvals for Two Innovative Biologics in the US and China

Fineline Cube Jan 9, 2024

Jiangxi Jemincare Group, a biopharmaceutical company based in China, has announced that it has received...

Company Medical Device

ShuWen Biotech’s MammaTyper Diagnostic Kit Receives NMPA Approval for Breast Cancer Molecular Classification

Fineline Cube Jan 9, 2024

ShuWen Biotech Co., Ltd, a biopharmaceutical company based in Zhejiang, has announced that its MammaTyper...

Company Drug

Allist Pharmaceuticals’ Furmonertinib and AstraZeneca’s Enhertu Earn Breakthrough Designations in China for NSCLC Treatments

Fineline Cube Jan 9, 2024

The Center for Drug Evaluation (CDE) in China has indicated on its website that Allist...

Company Drug

Thederma’s TAP-1503 Cream Receives Priority Review Status for Pediatric Atopic Dermatitis Treatment in China

Fineline Cube Jan 9, 2024

The Center for Drug Evaluation (CDE) website has indicated that China-based Thederma’s TAP-1503 cream is...

Company Drug

Innovent Biologics’ Mazdutide Achieves Positive Results in Phase III Clinical Trial for Overweight or Obesity

Fineline Cube Jan 9, 2024

Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...

Company Deals

Bain Capital-Backed Tenacia Strikes Deal with Praxis Precision Medicines for Essential Tremor Treatment

Fineline Cube Jan 9, 2024

Tenacia, a central nervous system (CNS) specialist incubated by Bain Capital, has entered into an...

Company Drug

Abbisko Therapeutics’ Pimicotinib Earns Orphan Drug Designation from EMA for TGCT Treatment

Fineline Cube Jan 9, 2024

Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced that it has...

Company Drug

Gilead’s Descovy Receives Additional Indication Approval from China’s NMPA for HIV-1 PrEP

Fineline Cube Jan 9, 2024

Gilead Sciences, Inc. (NASDAQ: GILD), a major player in the pharmaceutical industry in the U.S.,...

Company Deals

Bebig Medical Group Secures Over USD 14 Million in Series B Financing to Boost Radiotherapy Technology

Fineline Cube Jan 9, 2024

Bebig Medical Group, a Germany-based provider of high-quality radiation therapy products with a presence in...

Company Deals

Chengdu Kanghua Strikes Licensing Deal with HilleVax for Recombinant Norovirus Vaccine

Fineline Cube Jan 9, 2024

Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841), a biopharmaceutical company based in China, has...

Company Drug

CSBIO’s Multi-Kinase Inhibitor CSCJC3456 Gets Green Light for Clinical Trials in Advanced Solid Tumors

Fineline Cube Jan 9, 2024

Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255), a Chinese pharmaceutical company, has announced...

Posts pagination

1 … 406 407 408 … 654

Recent updates

  • Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma
  • Shanghai Leadingtac Secures FDA Clearance for Phase I Trial of LT-010391, First Oral KRAS-G12D Degrader in Clinical Development
  • China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive
  • FDA Grants Priority Review to Merck, Astellas, and Pfizer’s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer
  • Boehringer Ingelheim Opens AI & Machine Learning Hub in London, Commits €150M to Accelerate Drug Discovery for High-Unmet-Need Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma

Company Drug

Shanghai Leadingtac Secures FDA Clearance for Phase I Trial of LT-010391, First Oral KRAS-G12D Degrader in Clinical Development

Policy / Regulatory

China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive

Company Drug

FDA Grants Priority Review to Merck, Astellas, and Pfizer’s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.